Non-infective endocarditis

Harriet Hurrell, Ross Roberts-Thomson, Bernard D Prendergast

INTRODUCTION

Endocarditis is defined as inflammation of the endocardium, the lining of the cardiac chambers and valves, and characterised by vegetations, most commonly caused by infection with bacteria or fungi. Non-infective endocarditis, also known as non-bacterial thrombotic endocarditis (NBTE) or aseptic endocarditis, refers to a rare condition characterised by formation of sterile vegetations. Without treatment, these can lead to valve dysfunction, heart failure, systemic embolism and death. Herein, we review the pathophysiology, clinical features, diagnosis and treatment of NBTE.

BACKGROUND

The first description of sterile vegetations on the heart valves was provided by Zeigler in 1888.1 Libman and Sacks then published a case series of four patients in 1924 which associated these atypical lesions with systemic lupus erythematosus (SLE).2 These vegetations are not associated with an inflammatory response or bacteraemia and commonly occur as a result of fibrin deposition and platelet aggregation. Sterile vegetations can develop in a number of conditions, including autoimmune disease, malignancy and hypercoagulable states. Although Libman–Sacks endocarditis refers specifically to NBTE seen in patients with the autoimmune disorders SLE and antiphospholipid syndrome (APLS), other interchangeable terminology for NBTE includes verrucous endocarditis and marantic endocarditis.

A vegetation is defined as an oscillating intracardiac mass on a valve (or its supporting structure) or implanted material. The rapid evolution of echocardiographic imaging techniques has resulted in higher rates of vegetation detection in more recent studies using these developed imaging modalities.3 4

EPIDEMIOLOGY

NBTE is a rare condition and most commonly diagnosed at post-mortem. The exact incidence is unknown but rates of up to 3.7% have been reported at autopsy.5 6 The incidence increases with age (likely due to the association with malignancy) with no known gender predominance.6 7 NBTE has a well-known association with autoimmune conditions and malignancy.6 7 In the largest study of culture-negative endocarditis, NBTE accounted for 2.5% of cases.8 Patients with definite endocarditis but no underlying autoimmune or malignant condition were more likely to have a positive serum rheumatoid factor compared with those with confirmed aetiology, highlighting the likely under-estimation of immune-mediated causes.

Echocardiographic studies have found vegetations in 11% of patients with SLE and no evidence of infection.9 Although uncommon, NBTE has been reported in rheumatoid arthritis.8 10 There are isolated case reports of NBTE associated with rarer autoimmune conditions, including granulomatosis with polyangiitis, Behçet’s disease and adult-onset Still’s disease.11 12 Post-mortem studies have also identified NBTE in patients with HIV, although the incidence is lower than initially thought.13 NBTE is common in neoplastic conditions with one prospective study reporting a prevalence of 19% in patients with underlying malignancy (most frequently adenocarcinomas, particularly of the pancreas and lung).6 7 14–16

Coagulation abnormalities indicative of disseminated intravascular coagulation (DIC) have also been found in up to 50% of patients with NBTE, suggesting a strong relation with hypercoagulable states, including primary APLS, burns and sepsis.14–17

Table 1 summarises the conditions associated with NBTE and their reported prevalence. Antemortem diagnosis is rare and NBTE is therefore often underestimated. With improved imaging modalities, there is significant variability in the prevalence of NBTE reported in the literature. Patients often have a combination of conditions predisposing them to NBTE (such as malignancy and a hypercoagulable state).

PATHOPHYSIOLOGY

Deposition of sterile fibrin and platelets on the surface of valve leaflets is the pathological hallmark of NBTE (figure 1). Vegetations may be microscopic or large in size with a clustered, wart-like appearance, although diffuse leaflet thickening may develop in the chronic, treated phase of the disease.18 They may occur anywhere on the endocardial surface, with a
Table 1  Summary of conditions associated with non-bacterial thrombotic endocarditis and their reported prevalence

<table>
<thead>
<tr>
<th>Conditions associated with NBTE</th>
<th>Prevalence of NBTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune conditions:</td>
<td></td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>4%–43%</td>
</tr>
<tr>
<td>Antiphospholipid syndrome (primary and secondary)</td>
<td>41%</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>Unknown</td>
</tr>
<tr>
<td>Granulomatous with polyangitis</td>
<td>Single case report</td>
</tr>
<tr>
<td>Behcet’s</td>
<td>Single case report</td>
</tr>
<tr>
<td>HIV</td>
<td>Unknown</td>
</tr>
<tr>
<td>Malignancy:</td>
<td>19%</td>
</tr>
<tr>
<td>Most frequently adenocarcinomas</td>
<td>62% of patients with malignancy and NBTE</td>
</tr>
<tr>
<td>Pancreatic cancer most common</td>
<td>25%–50% of patients with malignancy and NBTE</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>25%–30% of patients with malignancy and NBTE</td>
</tr>
<tr>
<td>Hypercoagulable states:</td>
<td>Found in up to 50%</td>
</tr>
<tr>
<td>APLS (primary and secondary APLS)</td>
<td></td>
</tr>
<tr>
<td>Malignancy</td>
<td></td>
</tr>
<tr>
<td>Disseminated intravascular coagulopathy</td>
<td></td>
</tr>
<tr>
<td>Sepsis</td>
<td></td>
</tr>
<tr>
<td>Burns</td>
<td></td>
</tr>
</tbody>
</table>

APLS, antiphospholipid syndrome; NBTE, non-bacterial thrombotic endocarditis.

The aetiology of NBTE is poorly understood and a number of different interacting mechanisms (including circulating immune complexes, hypercoagulable states and carcinomatosis) may play a role, ultimately resulting in endothelial damage and exposure of the subendothelial connective tissue to circulating platelets (figure 2).

**Immune mechanisms**

Pathophysiological studies in patients with SLE have demonstrated deposition of immunoglobulins and complement complexes along the edges of valve leaflets and within valvular vegetations, suggesting a major pathogenic role of immune complexes in mediating valvar tissue injury. Patients with SLE and secondary APLS have a similar prevalence of valvular involvement to those with SLE alone and no detectable anticardiolipin antibodies. NBTE may also occur (though less commonly) in patients with primary APLS. Although it was originally thought that APLS promoted a hypercoagulable state with thrombus formation and NBTE, it is now recognised that it may also mediate valve damage by direct immune-mediated reactions. Patients with APLS and valve involvement have higher circulating levels of anticardiolipin antibodies directed against negatively charged phospholipids present in endothelial cell membranes.

**Hypercoagulable states**

Impaired antithrombotic mechanisms in patients with APLS, malignancy and hypercoagulable states are implicated in the pathogenesis of thrombosis and subsequent valve lesions. The instigating factor is unknown but it is likely that endothelial damage provides the foundation for deposition of platelets and fibrin in an already prothrombotic state.

In addition to APLS, there is an association between patients with coagulation abnormalities suggestive of DIC and NBTE. In one study, 50% of patients with DIC were found to have NBTE, supporting the view that these conditions are related and result from a hypercoagulable state.

Figure 1  (A) Histological section of the mitral valve showing thrombotic vegetations devoid of inflammation (Brock MA et al19). (B) Histology of a vegetation demonstrating a web-like mesh of fibrin and platelets (Llenas-Garcia J et al20).

predilection for the left-sided heart valves. Potential mechanisms include the combination of shear stress on the mitral valve arising from turbulent flow and oxidative stress compared with low pressure flow of de-oxygenated blood in the right heart. Unlike conventional infective endocarditis, these vegetations are not associated with inflammation or bacteraemia. The valves are usually previously undamaged but NBTE can also arise in patients with pre-existing valve disease.

In infective endocarditis, underlying damage to the valve endothelium through trauma or other phenomena is frequent. Bacteria then adhere to this damaged endothelium and propagate, resulting in formation of a vegetation that promotes activation of the clotting cascade with fibrin and platelet deposition over the clusters of bacteria. In turn, this often leads to valve destruction and failure, which is rare in NBTE.
Carcinomatosis

The association of NBTE with malignancy (particularly adenocarcinomas of the pancreas and lung) is well known. Macrophages interact with malignant cells to produce circulating cytokines (such as tumour necrosis factor and interleukin-1) that cause endothelial damage with consequent promotion of sterile thrombi and platelet deposition. These macrophages also stimulate production of clotting factors to create a hypercoagulable state. Patients with advanced malignancy may also have clotting abnormalities suggestive of DIC, further promoting a hypercoagulable state. The combination of these mechanisms results in thrombotic valve lesions in these patients.

Laboratory investigations

Blood cultures/microbiology: Diagnostic work-up for infective endocarditis should be performed to differentiate infective endocarditis from NBTE. Three sets of blood cultures should be taken prior to commencing antibiotic therapy. To differentiate between NBTE and culture-negative infective endocarditis, typical and atypical infective endocarditis organisms (including fungi, HACEK group, Coxiella or chlamydia) should be sought using specialised techniques. PCR may be performed on the tissue of explanted valves (or blood PCR if available) to look for fastidious organisms such as Tropheryma whippelii, Coxiella burnetii and Bartonella species, where appropriate. Serial negative blood cultures and atypical serology are required for a diagnosis of NBTE. However, negative blood cultures can be misleading and are observed in up to 30% of cases of infective endocarditis, often as a result of prior antibiotic therapy.

Blood tests: Extended coagulation screening and clotting factor assay should be performed, including prothrombin time, partial thromboplastin time, fibrinogen, thrombin time, D-dimers and cross-linked fibrin degradation products to assess for clotting disorders or evidence of a hypercoagulable state.

Immunological testing: Tumour markers, ANA, ENA, anti-dsDNA, rheumatoid factor, anticyclic citrullinated peptide antibodies and anti-β2-glycoprotein 1 antibodies should be measured to exclude any associated underlying autoimmune condition.
Figure 4  Transthoracic echocardiographic image (parasternal long axis) demonstrating a vegetation (arrowed) on the mitral valve in a patient with metastatic lung cancer and associated NBTE. NBTE: non-bacterial thrombotic endocarditis.

Figure 5  MRI brain of the same patient with end stage lung cancer, later diagnosed with NBTE, demonstrating multiple cerebral infarcts (arrowed). NBTE: non-bacterial thrombotic endocarditis.

**Imaging**

Echocardiography: Despite low diagnostic yield, a transthoracic echocardiogram should be performed to look for vegetations on the heart valves if NBTE is suspected. It is important to note that the echocardiogram may be normal if the vegetation has already embolised. Transoesophageal echocardiography has greater sensitivity than transthoracic imaging, particularly in patients with small vegetations (<5 mm) and should be performed in patients with a normal transthoracic echocardiogram and a strong suspicion of NBTE. Vegetations of infective and non-infective aetiology cannot be differentiated on echocardiography. However, vegetations seen in NBTE are usually small (<1 cm), broad based and irregular in shape (figure 4).

Cardiac magnetic resonance (CMR): There are only limited case reports describing the role of CMR in diagnosis of NBTE. The higher resolution of CMR should enable identification of smaller valve structures and it may well have a diagnostic role in the future.

Positron emission tomography (PET): Although commonly used in the diagnosis of prosthetic valve infective endocarditis or device-related infection, CT-PET has low sensitivity in native valve endocarditis and there are limited data concerning its use in the diagnosis of NBTE. A single case report has demonstrated increased tracer uptake in valve lesions associated with NBTE.

Whole-body CT and MRI brain imaging should be performed in patients with suspected NBTE to look for evidence of systemic embolism (figure 5).

**Histology**

Imaging tools are unable to distinguish between sterile vegetations and those of infective origin. Diagnosis can therefore only be confirmed on histological assessment.

Vegetations vary in size and are usually located at sites of turbulent flow along the lines of valve closure or on the leaflets themselves. The valve lesions have similar histological appearances regardless of the underlying aetiology, consisting of degenerating platelets interwoven with fibrin strands, granulomatous tissue and fibrotic foci (figure 6). Inflammatory cells and infective microorganisms are absent. Histopathological examination also allows the diagnosis of primary cardiac malignancies, such as angiosarcoma and myxoma.

In summary, the diagnosis of NBTE can only be confirmed by demonstration of platelet thrombi at autopsy or on histological examination of surgical specimens. A high index of clinical suspicion is therefore required for diagnosis. Patients with a high likelihood of the diagnosis of NBTE are those with a predisposing condition, features of systemic emboli and valve lesions with no evidence of associated infection (or valve masses that fail to respond to antibiotic therapy) (table 2).

**TREATMENT**

Treatment of NBTE is aimed at identification and treatment of the underlying condition, and reducing the risk of systemic embolism. Surgery is rarely indicated, except in those patients with haemodynamic compromise or refractory heart failure. Unless there is a contraindication, all patients with a clinical diagnosis of NBTE should receive anticoagulant therapy.

Treatment of the underlying disease

Treatment should target the underlying autoimmune condition or malignancy, although there are limited data to demonstrate impact on the valve lesions. Underlying malignancy is often advanced with poor prognosis and palliative treatment may be most appropriate.
Table 2 Clinical features and diagnostic investigations differentiating NBTE from infective endocarditis

<table>
<thead>
<tr>
<th></th>
<th>NBTE</th>
<th>Infective endocarditis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predisposing conditions:</td>
<td>Autoimmune (SLE/APLS)</td>
<td>Underlying valve pathology</td>
</tr>
<tr>
<td></td>
<td>Malignancy</td>
<td>History of intravenous drug use</td>
</tr>
<tr>
<td></td>
<td>Hypercoagulable states</td>
<td>Central lines/indwelling catheters</td>
</tr>
<tr>
<td>Clinical features:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>–</td>
<td>++</td>
</tr>
<tr>
<td>Systemic embolism</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Heart failure</td>
<td>– (rare)</td>
<td>++</td>
</tr>
<tr>
<td>Valve dysfunction</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td>Blood cultures/serology</td>
<td>Serial negative blood cultures</td>
<td>+ (Negative blood cultures in up to 30% of cases)</td>
</tr>
<tr>
<td>Echocardiographic features:</td>
<td>Frequent false-negative results: vegetation may have already embolised</td>
<td>Mobile mass of variable location</td>
</tr>
<tr>
<td></td>
<td>Vegetations often small (&lt;1 cm), broad based and irregular in shape</td>
<td>Valve destruction/dysfunction common</td>
</tr>
<tr>
<td></td>
<td>Predilection for left-sided heart valves</td>
<td>Aortic root abscess often seen</td>
</tr>
<tr>
<td>MRI brain for cerebral emboli</td>
<td>Multiple, small disseminated infarcts</td>
<td>Usually single territory large infarct</td>
</tr>
</tbody>
</table>

NBTE, non-bacterial thrombotic endocarditis.

Patients with SLE should receive immunosuppressant therapy under the care of a specialist rheumatology team. NBTE associated with SLE may arise at any stage of the disease process (including the chronic treatment phase) and appears to be unrelated to disease activity.18 34 Treatment does not reduce the incidence of associated valve lesions—indeed, their incidence appears to have increased with improved immunological management and prolonged survival.

**Anticoagulation**

Systemic embolism from friable vegetations is common and unless there is a contraindication, all patients with a diagnosis of NBTE should be anticoagulated with low molecular weight heparin, unfractionated heparin or warfarin.7 35 Some studies have suggested that warfarin is less effective than heparin in preventing thromboembolic events in patients with malignancy.7 36 37 There is currently no evidence supporting the use of non-vitamin K antagonist oral anticoagulants. A recent trial comparing warfarin and rivaroxaban in the treatment of thrombotic APLS suggested an increased risk for recurrent thrombosis in rivaroxaban-treated patients.38 The risk of recurrent embolism is high and anticoagulation should be continued indefinitely unless there are major bleeding complications.

Heparin reduces the incidence of recurrent cerebral emboli (without promoting brain haemorrhage) in patients with NBTE presenting with ischaemic stroke.39 Management should be undertaken in conjunction with a Stroke Team, with cerebral imaging prior to anticoagulation and a low threshold for repeat imaging if new neurological signs are detected.

**Surgery**

Valve surgery is seldom required in the treatment of NBTE since the valve itself is usually undamaged, recurrent vegetations are common and the risk of surgery often outweighs the potential benefits (particularly in patients with advanced malignancy).7 14

There are no current guidelines as to which patients should undergo surgery, but intervention may be considered in patients who are haemodynamically unstable and those with acute heart failure of valvular origin, recurrent thromboembolism despite therapeutic anticoagulation or large left-sided vegetations with high embolic potential. Valve sparing surgery is frequently feasible35 (figure 7).

**PROGNOSIS**

The condition is rare and no formal studies have examined the prognosis of patients with NBTE. Clinical experience demonstrates that the prognosis is usually poor, largely due to the strong association with advanced malignancy and recurrent systemic embolism.7–16 In one study, the incidence of ischaemic cerebral events in Libman–Sachs patients was 15% over 4-year follow-up.9

**FOLLOW-UP**

There are no current guidelines for the follow-up of patients with NBTE, although frequent monitoring (initially every 2–6 weeks) is important to exclude recurrent systemic embolism, ensure adequate anticoagulation and freedom from...
CONCLUSION

NBTE is a rare condition associated with autoimmune disease, malignancy and hypercoagulable states, and characterised by sterile friable vegetations composed of fibrin and platelets with high risk of systemic embolism. Most patients are asymptomatic and the condition is commonly diagnosed at post-mortem. A high index of clinical suspicion is therefore required for diagnosis. Management requires differentiation of NBTE from infective endocarditis, definition of the underlying cause, assessment of valve lesions with echocardiography and prevention of systemic embolism by means of anticoagulant treatment. Surgery is rarely indicated, except in patients with haemodynamic compromise, valve failure or high risk of embolism.

CONTRIBUTORS

All the listed authors on this paper fulfil the criteria of authorship. They have all substantially contributed to the content of this review article and have approved the final submitted version.

FUNDING

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

COMPETING INTERESTS

None declared.

PATIENT AND PUBLIC INVOLVEMENT

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

PATIENT CONSENT FOR PUBLICATION

Not required.

PROVENANCE AND PEER REVIEW

Commissioned; internally peer reviewed.

DATA AVAILABILITY STATEMENT

All data relevant to the study are included in the article or uploaded as supplementary information.

AUTHOR NOTE

References which include a * are considered to be key references.
REFERENCES